HC Wainwright Issues Pessimistic Outlook for LBRX Earnings

LB Pharmaceuticals Inc (NASDAQ:LBRX) – Equities researchers at HC Wainwright dropped their Q2 2026 earnings per share (EPS) estimates for LB Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.77) for the quarter, down from their previous forecast of ($0.73). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for LB Pharmaceuticals’ current full-year earnings is ($3.55) per share. HC Wainwright also issued estimates for LB Pharmaceuticals’ Q3 2026 earnings at ($0.97) EPS, FY2026 earnings at ($3.61) EPS, Q1 2027 earnings at ($1.25) EPS, Q2 2027 earnings at ($1.29) EPS, Q4 2027 earnings at ($1.41) EPS and FY2027 earnings at ($5.30) EPS.

LBRX has been the subject of a number of other research reports. Roth Mkm reissued a “buy” rating and set a $37.00 price objective on shares of LB Pharmaceuticals in a research report on Sunday, May 17th. Craig Hallum began coverage on LB Pharmaceuticals in a research report on Friday, April 10th. They set a “buy” rating and a $36.00 price objective for the company. Finally, Stifel Nicolaus lifted their price objective on LB Pharmaceuticals from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $38.40.

LB Pharmaceuticals Trading Down 1.9%

LBRX opened at $27.80 on Thursday. The stock has a market cap of $797.30 million and a price-to-earnings ratio of -16.07. LB Pharmaceuticals has a 1 year low of $13.36 and a 1 year high of $33.47. The stock has a fifty day moving average price of $28.00 and a 200 day moving average price of $23.50.

LB Pharmaceuticals (NASDAQ:LBRX) last issued its earnings results on Tuesday, May 12th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.08.

Hedge Funds Weigh In On LB Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Deep Track Capital LP bought a new position in LB Pharmaceuticals during the third quarter valued at about $52,941,000. RA Capital Management L.P. increased its stake in shares of LB Pharmaceuticals by 24.3% in the fourth quarter. RA Capital Management L.P. now owns 2,208,604 shares of the company’s stock worth $49,164,000 after purchasing an additional 431,646 shares during the period. TCG Crossover Management LLC bought a new position in shares of LB Pharmaceuticals in the third quarter worth about $27,554,000. JPMorgan Chase & Co. increased its stake in shares of LB Pharmaceuticals by 56.1% in the fourth quarter. JPMorgan Chase & Co. now owns 1,611,482 shares of the company’s stock worth $35,872,000 after purchasing an additional 578,879 shares during the period. Finally, Commodore Capital LP bought a new position in shares of LB Pharmaceuticals in the third quarter worth about $23,685,000.

LB Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.